DECADRON Eye Drops Cleared for Continued Generic Production
Published Date: 4/9/2025
Notice
Summary
The FDA says DECADRON eye drops (0.1% phosphate) weren’t pulled from shelves because of safety or effectiveness problems. This means generic drug makers can keep getting approval to sell their versions, so patients and pharmacies won’t face shortages or price hikes. Everyone who uses or sells this medicine can breathe easy—no sudden changes or costs coming!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
DECADRON Generics Remain Approvable
If you use DECADRON eye drops (dexamethasone sodium phosphate) equivalent to 0.1 percent phosphate, the FDA has determined the product was not withdrawn for reasons of safety or effectiveness. That means the FDA will not begin procedures to withdraw approvals of abbreviated new drug applications (ANDAs) that refer to this product, and the agency will continue to approve ANDAs that refer to it so long as they meet legal and regulatory requirements.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in